Understanding patients with transthyretin cardiac amyloidosis
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine
University Hospital, Strasbourg, France · NCT06907836
This study looks at patients with transthyretin cardiac amyloidosis to learn more about how the disease affects their hearts and overall health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06907836 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize a cohort of patients diagnosed with transthyretin cardiac amyloidosis (ATTR-CA) at the University Hospital in Strasbourg, France. It focuses on the prevalence and natural history of the disease, particularly in relation to heart failure with preserved ejection fraction. The study will analyze patient data collected from hospitalizations in internal medicine over a ten-year period, from 2013 to 2023, to better understand the progression and outcomes of ATTR-CA. By examining this cohort, the study seeks to shed light on the underdiagnosed nature of the condition and its impact on patient survival.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with transthyretin amyloidosis following hospitalization in internal medicine at the University Hospital of Strasbourg.
Not a fit: Patients with types of amyloidosis other than ATTR or those who have opted out of data reuse for research will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of ATTR-CA, leading to improved diagnosis and management strategies for patients.
How similar studies have performed: While there is limited data on similar observational studies specifically focusing on ATTR-CA, the increasing recognition of the condition suggests that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sujet majeur (≥18 ans) * Diagnostic d'amylose à TTR suite à une hospitalisation en médecine interne aux HUS entre 01/01/2013 au 31/12/2023. Exclusion Criteria: * Subject (and/or their legal representative, if applicable) who has expressed their opposition to the reuse of their data for scientific research purposes. * Type of amyloidosis other than ATTR after review of the medical record (immunological assessment, imaging assessment, expert report).
Where this trial is running
Strasbourg
- Service de Médecine Interne - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Emmanuel ANDRES, MD, PhD
- Email: emmanuel.andres@chru-strasbourg.fr
- Phone: 33 3 88 12 71 33
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiac Amyloidosis, Internal medicine